Samlyn Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Samlyn Capital’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-154,706	Closed	-$18.3M	–	134
2022 Q1	$18.3M	Hold	154,706	–	–	0.26%	76
2021 Q4	$21.3M	Hold	154,706	–	–	0.29%	68
2021 Q3	$21.5M	Hold	154,706	–	–	0.29%	77
2021 Q2	$15M	Hold	154,706	–	–	0.22%	76
2021 Q1	$10.6M	Hold	154,706	–	–	0.15%	88
2020 Q4	$13.3M	Sell	154,706 -238,250	-61%	-$20.2M	0.19%	89
2020 Q3	$25.5M	Sell	392,956 -143,574	-27%	-$9.41M	0.46%	69
2020 Q2	$39.2M	Buy	+536,530	New	+$28.6M	0.73%	48
2019 Q2	–	Sell	-729,178	Closed	-$37.5M	–	160
2019 Q1	$37.5M	Sell	729,178 -192,358	-21%	-$8.31M	0.89%	43
2018 Q4	$34.1M	Buy	921,536 +227,432	+33%	+$8.2M	0.81%	43
2018 Q3	$26.1M	Buy	694,104 +307,380	+79%	+$11.3M	0.59%	63
2018 Q2	$15.3M	Sell	386,724 -14,598	-4%	-$463K	0.36%	85
2018 Q1	$10.3M	Buy	+401,322	New	+$12M	0.23%	89

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samlyn Capital's BHVN Position: Q2 2022 in Review

Samlyn Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 154,706 shares — an estimated $18.3M sold.

Samlyn Capital first reported a position in BHVN in Q1 2018 and held it in 13 quarters. The position peaked at $39.2M in Q2 2020. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Samlyn Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Samlyn Capital sold 154,706 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $18.3M.
Samlyn Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 13 quarters.
Samlyn Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $39.2M in Q2 2020.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Samlyn Capital's 13F filing for Q2 2022, filed 15 Aug 2022.